

## SYNTHETIC STUDIES OF 1, 2, 3, 4-TETRAHYDRO-1, 3, 4-TRIOXO- $\beta$ -CARBOLINE ALKALOIDS I<sup>†</sup>

Hideharu Suzuki, Kayoko Shinpo, Towako Yamazaki, Sachiko Niwa,  
Yuusaku Yokoyama, and Yasuoki Murakami\*

School of Pharmaceutical Sciences, Toho University,  
2-2-1 Miyama, Funabashi, Chiba 274, Japan


**Abstract** - A simple and efficient total synthesis of 1, 2, 3, 4-tetrahydro-1, 3, 4-trioxo- $\beta$ -carboline (**1**) was accomplished *via* C<sub>3</sub>-selective acylation of indole-2-carboxylate (**5**). On the course of this study, we found that the cyclization of *N*-(2-indolecarbonyl)glycine (**8a**) with PPA gave only an *N*-cyclized 6-membered ring (**10a**), whereas *N*-(2-indolecarbonyl)- $\beta$ -alanine (**8b**) gave a C<sub>3</sub>-cyclized 7-membered ring (**9b**) as a main product.

Recently 1, 2, 3, 4-tetrahydro-1, 3, 4-trioxo- $\beta$ -carbolines ( $\beta$ -carboline-triones) (**1**, **2**) were isolated from the *Simaroubaceae* plant as minor alkaloids<sup>2a</sup> along with 4-oxygenated  $\beta$ -carbolines<sup>2b</sup>(**3**). These have a highly oxygenated C-ring which is a novel skeleton in natural  $\beta$ -carbolines, and are expected to have some biological activity, as some of **3** have shown biological activities. However, the activities have not been examined, because of their minor productions from nature. One of these (**1**) has been known compound derived from natural brevicolline (**4**) by CrO<sub>3</sub>-oxidation during the structural determination.<sup>3</sup>




**1**: R = H

**2**: R = OMe  
(Picrasidine-V)



**3**




**4**


Scheme I

<sup>†</sup> Dedicated to the memory of late Prof. Yoshio Ban.



$^1\text{H-Nmr } \delta$  (ppm) :


NOESY and C-H COSY observation



Scheme IV

Thus we also re-examined the cyclization of **8b**, which forms a 7-membered ring, and found that the two kinds of compounds were formed from **8b**, being different from Röder's result.<sup>5</sup> Surprisingly the major product (77%) was C<sub>3</sub>-cyclized one (**9b**), while the minor product was *N*-cyclized one (12%) (**10b**), being in contrast to the cyclization of **8a**. Their structures were elucidated clearly by assigning the 7.48 ppm of indolic C<sub>3</sub>-H (**10b**) and 12.48 ppm of *N*-H (**9b**). (Scheme IV). The reason for this interesting difference in cyclization between 6-membered ring and 7-membered ring is unknown.

Other cyclization conditions of **8a** and conversion of *N*-cyclized compound (**10a**) to C<sub>3</sub>-cyclized product (**9a**), failed to give the desired C<sub>3</sub>-cyclized product (**9a**). Hence we synthesized **9a** via a more confident route described in scheme V.



a:  $(\text{CH}_3\text{CO})_2\text{O}$ ,  $\text{AlCl}_3$  /  $\text{ClCH}_2\text{CH}_2\text{Cl}$ , room temperature, 10 h    b:  $\text{CuBr}_2$  [1.8 mol(0.9 eq.)] /  $\text{AcOEt}$ , reflux, 1 h    c: hexamethylenetetramine /  $\text{CHCl}_3$ , room temperature, 1 h    d: c.HCl /  $\text{EtOH}$ , 55°, 1 h  
e:  $\text{Et}_3\text{N}$  /  $\text{EtOH}$ , room temperature, 10 h

Scheme V

The C<sub>3</sub>-selective Friedel-Crafts acylation<sup>7</sup> of **5** gave the 3-acetyl product (**11**), and selective bromination of the  $\alpha$ -carbon of the carbonyl group with CuBr<sub>2</sub> gave the bromoacetyl compound (**12**) in good yield. The reaction of **12** with hexamethylenetetramine, followed by hydrolysis with conc. HCl gave the  $\alpha$ -aminoketone hydrochloride(**14**). The treatment of **14** with Et<sub>3</sub>N gave unexpectedly the  $\beta$ -carboline-trione (**1**) without isolation of **9a**,<sup>8</sup> as a result of cyclization followed by spontaneous air oxidation. Consequently we accomplished a total synthesis of  $\beta$ -carboline-trione (**1**). Synthesized compound (**1**) was identical with the natural product (**1**).

During the pharmacological screening examination of the synthetic sample, the compound (**1**) was found to possess a weak cytotoxicity against the P-388 mouse leukemia cell (IC<sub>50</sub> = 13.6  $\pm$  0.5  $\mu$ g / ml), HOC-21 human ovarian cancer cell (IC<sub>50</sub> = 25.2  $\pm$  1.3  $\mu$ g / ml) and MKN-28 human cancer cell (from human stomach) (IC<sub>50</sub> = 16.1  $\pm$  1.3  $\mu$ g / ml). Now we are interested in the activities of Picrasidine-V (**2**) and other analogues of **1**. The syntheses of these are now in progress.

#### ACKNOWLEDGMENT

We are grateful to Daiichi Pharmaceutical Co. Ltd. for the pharmacological screening test of **1**, and to Prof. T. Ohmoto and Dr. K. Koike, Toho University, for correlation of **1** with the natural product.

#### REFERENCES AND NOTES

1. This paper is part XXXVII of "Synthetic Studies on Indoles and Related Compounds." Part XXXVI: Y. Yokoyama, T. Matsumoto, and Y. Murakami, *J. Org. Chem.*, 1995, **60**, 1486.
2. a) K. Koike, T. Ohmoto, and K. Ikeda, *Phytochemistry*, 1990, **29**, 3060.  
b) T. Ohmoto and K. Koike, *Chem. Pharm. Bull.*, 1983, **31**, 3198.
3. P. A. Vember, I. V. Terent'eva, and G. V. Lazur'evskii, *Khim. Prir. Soedin.*, 1967, **3**, 249 (*Chem. Abstr.*, 1967, **67**, 108816t).
4. H. Suzuki, Y. Yokoyama, C. Miyagi, and Y. Murakami, *Chem. Pharm. Bull.*, 1991, **39**, 2170.
5. J. Pigulla and E. Röder, *Liebigs Ann. Chem.*, **1978**, 1390.
6. Röder assigned the signals of 8.2 - 8.4 ppm as N-H's of indole and imido group.
7. Y. Murakami, M. Tani, K. Tanaka, and Y. Yokoyama, *Chem. Pharm. Bull.*, 1988, **36**, 2023.
8. The early stage of this reaction gave a complex mixture on tlc (presumably, **9a** was formed at first, and oxidation occurred gradually on tlc). However, the reaction mixture gave a single spot of the target compound (**1**) on tlc few hours later.